Upcoming Events
Log In
Pricing
Free Trial

Wk 3, Case 5 - Practice

HIDE

Pre-Treatment: Recently diagnosed left UOQ breast invasive ductal carcinoma, presenting for initial staging and treatment planning.

Post-Treatment: Stage IIIB (cT3 cN3c M0) left UOQ grade 3, ER negative, PR weak 70%, HER2 + invasive ductal carcinoma of breast, status post 7 cycles TCHP, presenting for treatment response assessment and pre-surgical planning.

FDG was the tracer used for both.

Based on the post-treatment follow-up 18F-FDG PET/CT, what kind of response did the patient have to their treatment?

PrevNext

Report

Faculty

Riham El Khouli, MD

Associate Professor of Radiology, Chief, Division of Nuclear Medicine/Molecular Imaging & Radiotheranostics

University of Kentucky

Michael F. Shriver, MD

Director of Nuclear Medicine

Proscan-NCH Imaging

Tags

PET

Nuclear Medicine

CT

© 2025 Medality. All Rights Reserved.

Contact UsTerms of UsePrivacy Policy